Journal of neuro-AIDS · 1996
Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Counihan T, Venna N, Craven D, Sabin T D
Аннотация
OBJECTIVE: To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).
DESIGN: Open label, uncontrolled study.
SETTING: Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.
PATIENTS: Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.
INTERVENTION: Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.
RESULTS: None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.
CONCLUSIONS: Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.
DESIGN: Open label, uncontrolled study.
SETTING: Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.
PATIENTS: Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.
INTERVENTION: Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.
RESULTS: None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.
CONCLUSIONS: Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.